As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.
6 Analysts have issued a Exicure Inc forecast:
6 Analysts have issued a Exicure Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -9.08 -9.08 |
82%
82%
|
|
| EBIT (Operating Income) EBIT | -9.31 -9.31 |
86%
86%
|
|
| Net Profit | -9.23 -9.23 |
130%
130%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.
| Head office | United States |
| CEO | Andy Yoo |
| Employees | 7 |
| Founded | 2011 |
| Website | www.exicuretx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


